Rivaroxaban (Xarelto) is now approved in Australia for patients with severe renal impairment down to a creatinine clearance of 15 mL/min. The change brings the DOACs use in Australia into line with other countries including in Europe, the US and Canada. Associate Professor Martin Gallagher, a nephrologist and program director of Acute Kidney Injury and ...
Use of rivaroxaban extended to severe renal impairment
By Mardi Chapman
16 Jun 2020